TNYA
HealthcareTenaya Therapeutics, Inc.
$0.73
$-0.01 (-0.95%)
Jan 5, 2026
Price History (1Y)
Analysis
Tenaya Therapeutics, Inc. is a biotechnology company listed in the Healthcare sector with an employee base of 97 individuals. The company's market capitalization stands at $157.70M. Financially, Tenaya Therapeutics has reported significant losses, with net income totaling -$94,258,000 and EBITDA at -$88,510,000 over the trailing twelve months. Free cash flow is also negative, amounting to -$40,699,000. The company maintains a cash balance of $56.31M while carrying debt of $11.53M. Tenaya Therapeutics' valuation metrics reveal a P/E ratio of -1.48 and an EV/EBITDA of -0.88, indicating significant losses and potential for future growth or decline. The company's price to book ratio is 1.44, suggesting a relatively modest valuation compared to its assets.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Tenaya Therapeutics, Inc.
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company's lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Visit website →Key Statistics
- Market Cap
- $157.70M
- P/E Ratio
- N/A
- 52-Week High
- $2.35
- 52-Week Low
- $0.36
- Avg Volume
- 5.14M
- Beta
- 3.19
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 97